Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Equity Average (2016 - 2025)

Historic Equity Average for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $51.4 million.

  • Protalix BioTherapeutics' Equity Average rose 6849.29% to $51.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.4 million, marking a year-over-year increase of 6849.29%. This contributed to the annual value of $38.4 million for FY2024, which is 23485.98% up from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Equity Average of $51.4 million as of Q3 2025, which was up 6849.29% from $47.6 million recorded in Q2 2025.
  • Protalix BioTherapeutics' Equity Average's 5-year high stood at $51.4 million during Q3 2025, with a 5-year trough of -$11.1 million in Q4 2022.
  • For the 5-year period, Protalix BioTherapeutics' Equity Average averaged around $17.2 million, with its median value being $20.0 million (2023).
  • In the last 5 years, Protalix BioTherapeutics' Equity Average plummeted by 62794.77% in 2022 and then soared by 75775.54% in 2024.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Equity Average stood at -$2.9 million in 2021, then plummeted by 280.46% to -$11.1 million in 2022, then surged by 424.17% to $35.9 million in 2023, then increased by 5.34% to $37.8 million in 2024, then soared by 35.91% to $51.4 million in 2025.
  • Its Equity Average stands at $51.4 million for Q3 2025, versus $47.6 million for Q2 2025 and $44.2 million for Q1 2025.